PXD101 in Treating Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well PXD101 works in treating patients with relapsed or
refractory acute myeloid leukemia or older patients with newly diagnosed acute myeloid
leukemia. PXD101 may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth and by blocking blood flow to the cancer.